导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.81% | 1538/4773 |
| 近一周 | -1.76% | 2756/5465 |
| 近一月 | -3.42% | 2484/5421 |
| 近一季 | -5.18% | 1990/5231 |
| 近半年 | 3.20% | 956/4920 |
| 近一年 | 8.23% | 1357/4394 |
| 近两年 | 57.75% | 1298/2954 |
| 近三年 | 37.31% | 834/2253 |
| 成立以来 | 122.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.58% 3293/4961 |
15.90% 1619/5312 |
- - |
- - |
| 2025 | 19.90% 2170/4813 |
1.69% 1572/3635 |
1.18% 2433/4076 |
15.12% 2844/4524 |
1.24% 1458/4813 |
| 2024 | 19.65% 511/3463 |
2.73% 719/2808 |
-0.51% 775/3014 |
17.38% 1202/3129 |
-0.27% 1365/3463 |
| 2023 | -11.72% 1421/2656 |
2.53% 1341/2280 |
-5.60% 1504/2385 |
-1.90% 595/2515 |
-7.02% 2016/2655 |
| 2022 | -17.33% 577/2207 |
-12.20% 588/1919 |
8.38% 368/2016 |
-14.17% 1040/2113 |
1.22% 1340/2208 |
| 2021 | 2.98% 624/1822 |
-1.22% 451/1255 |
7.28% 687/1330 |
-4.71% 729/1466 |
1.99% 731/1822 |
| 2020 | 33.14% 464/1250 |
-8.14% 590/1028 |
16.44% 438/1067 |
11.14% 475/1164 |
11.99% 504/1184 |
| 2019 | 36.53% 356/1092 |
24.89% 488/754 |
0.28% 179/804 |
1.56% 387/850 |
7.34% 450/918 |
| 2018 | -20.72% 198/834 |
- - |
- - |
- - |
-11.07% 247/691 |
| 2017 | 21.28% 167/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.47% 141/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏沪深300指数增强A VS. 长安沪深300非周期A(740101) |